ArticleNature medicine2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Open access · greenAbstract readCase Reports
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 397 papers.
0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed
26.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
397 citing papers in PubMed, 630 citations in OpenAlex.
- Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Lancet (London, England) · 2023Trial
- Ultrasound controllable and antigen-independent killing viaMolecular therapy. Oncology · 2026Article
- Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for 'off-the-shelf' immunotherapy.Haematologica · 2026Article
- The evolving role of cytokines for CAR-T cell manufacturing and beyond.Nature biomedical engineering · 2026Review
- Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- TRAC in vivo: culmination of CAR and vector engineering.Cell research · 2026Article
- Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.Med (New York, N.Y.) · 2026Article
- The TCR in CAR T cell therapy: use it or lose it?Cancer gene therapy · 2026Review
- Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges.Molecular biology reports · 2026Review
- Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors.Molecular therapy. Oncology · 2026Review
- Challenges and advances in CAR-T cell therapy for B-ALL.Biomarker research · 2026Review
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- Article
- Article
- Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function.Signal transduction and targeted therapy · 2026Article
- Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.Cancer research · 2026Review
- Memory programming and new manufacturing paradigms in CAR-T cell therapy.Cancer gene therapy · 2026Review
- Article
- Article
- Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies.International journal of molecular sciences · 2026Review
337 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors at 6 institutions in 1 country.
Marco Ruella *Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4301-5811
Jun Xu *Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
David M Barrett *Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Joseph A FraiettaCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Tyler J ReichCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0178-1411
David E AmbroseCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Michael KlichinskyCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Olga ShestovaCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Prachi R PatelCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Irina KulikovskayaCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Farzana NazimuddinCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Vijay G BhojCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Elena J OrlandoNovartis Institutes for Biomedical Research, Cambridge, MA, USA.
Terry J FryUniversity of Colorado, Children's Hospital Colorado, Denver, CO, USA.ORCID http://orcid.org/0000-0001-8044-5226
Hans BitterNovartis Institutes for Biomedical Research, Cambridge, MA, USA.
Shannon L MaudeDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Bruce L LevineCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6971-8465
Christopher L NoblesDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Regina M YoungCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
John SchollerCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Saar I GillCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Carl H JuneCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.ORCID http://orcid.org/0000-0003-0241-3557
Stephan A GruppDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Simon F LaceyCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
J Joseph MelenhorstCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
University of Pennsylvania · USChildren's Hospital of Philadelphia · USParker Institute for Cancer Immunotherapy · USNovartis (United States) · USChildren's Hospital Colorado · USTranslational Therapeutics (United States) · US
Funding
Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.P01CA214278 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CARL H. JUNE · 2017 to 2026
$26.8MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MIMMUNOTHERAPY WITH CAR T CELLSR01CA120409 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H., ZHAO, YANGBING · 2006 to 2016
$2.7MResistance To Targeted Immunotherapies:CART19 as a ParadigmR00CA212302 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUELLA, MARCO · 2018 to 2020
$608kResistance To Targeted Immunotherapies:CART19 as a ParadigmK99CA212302 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUELLA, MARCO · 2017 to 2018
$348kNCI NIH HHS K99 CA212302NCI NIH HHS P01 CA214278NCI NIH HHS R00 CA212302NCI NIH HHS R01 CA120409NCI NIH HHS T32 CA009140
Abstract
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19
Indexed as
AdultAntigens, CD19B-LymphocytesCell- and Tissue-Based TherapyDrug Resistance, NeoplasmEpitopesHumansLeukemiaMaleReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesYoung AdultAntigens, CD19CD19 molecule, humanEpitopesReceptors, Antigen, T-CellReceptors, Chimeric Antigentisagenlecleucel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.